Together, these data suggest that ICOS agonist treatment during acute IAV infection has a beneficial effect on immune-mediated influenza pneumonia, most likely caused by an increased Treg/CD8+ T cell ratio, supporting the idea that ICOS can be considered a promising molecular target for future development of specific in vivo immune intervention strategies. This evidence concerns the gene CD8A and pneumonia.